Please login to the form below

Not currently logged in

protease inhibitor

This page shows the latest protease inhibitor news and features for those working in and with pharma, biotech and healthcare.

Pardes Biosciences, backed by Gilead and Foresite, goes public to advance lead COVID-19 antiviral drug

Pardes Biosciences, backed by Gilead and Foresite, goes public to advance lead COVID-19 antiviral drug

Pardes’ lead oral antiviral drug candidate is designed to inhibit the main protease of SARS-CoV-2. ... COVID-19 has been a global medical catastrophe. Over the past year we have been focused on bringing forward PBI-0451, a viral protease inhibitor that

Latest news

More from news
Approximately 2 fully matching, plus 77 partially matching documents found.

Latest Intelligence

  • Forging a path in specialty care Forging a path in specialty care

    Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA

  • Pharma deals in May 2015 Pharma deals in May 2015

    The agreement covers ACH 3102, ACH 3422 and sovaprevir. The intention is to trial a combination of ACH 3102 with a NS3/4A HCV protease inhibitor plus an NS5B HCV polymerase ... inhibitor. ACH 3102 has been granted fast track designation by the FDA.

  • Deal Watch table for June 2013 Deal Watch table for June 2013

    1, 000. Aragon Pharmaceuticals / J&J. Acquisition. Includes ARN 509 (second generation androgen receptor signalling inhibitor) for castration-resistant prostate cancer (phase II). ... BL8030, second generation protease inhibitor in development for

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....